New Zealand markets closed

Achilles Therapeutics plc (ACHL)

NasdaqGS - NasdaqGS Delayed price. Currency in USD
Add to watchlist
0.9020-0.0050 (-0.55%)
At close: 04:00PM EDT
0.8752 -0.03 (-2.97%)
After hours: 07:55PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 38.52M
Enterprise value -69.59M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.30
Enterprise value/revenue N/A
Enterprise value/EBITDA 1.74

Trading information

Stock price history

Beta (5Y monthly) 1.34
52-week change 3-10.69%
S&P500 52-week change 323.76%
52-week high 31.7600
52-week low 30.7400
50-day moving average 30.8629
200-day moving average 30.9357

Share statistics

Avg vol (3-month) 3212.3k
Avg vol (10-day) 336.17k
Shares outstanding 542.7M
Implied shares outstanding 642.7M
Float 824.93M
% held by insiders 16.52%
% held by institutions 157.23%
Shares short (15 May 2024) 413.81k
Short ratio (15 May 2024) 40.07
Short % of float (15 May 2024) 40.05%
Short % of shares outstanding (15 May 2024) 40.03%
Shares short (prior month 15 Apr 2024) 437.83k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-25.08%
Return on equity (ttm)-40.84%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -66.12M
Net income avi to common (ttm)-64.43M
Diluted EPS (ttm)-1.6000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)112.32M
Total cash per share (mrq)2.73
Total debt (mrq)4.21M
Total debt/equity (mrq)3.23%
Current ratio (mrq)9.63
Book value per share (mrq)3.17

Cash flow statement

Operating cash flow (ttm)-48.1M
Levered free cash flow (ttm)-30.96M